CHENGDU – December 04, 2023 (XYZ Newswire) Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment f
CHENGDU – April 17, 2023 (XYZ Newswire) Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial of t
On February 8, 2023(PT, UTC-8), TechnoDermaMedicines Inc.(hereinafter referred to as "TechnoDerma"), which focuses on the R&Dof new topicaldrugs, officially announced that it had initiatedthe phase I clinical trial of its TDM-180935 topical
On January 13, TechnoDermaannounced that it has recently completed a series A+ financing of tens of millions of RMB. Benefit fromthe capital market's favor and high recognition of the company's hair and eczema dermatitis clinical pipelines, the co
On Aug 9th, 2022, US Pacific Time, Technoderma Medicines (TDM), a drug discovery startup specialized in dermatology indications based at Jiaxing, China,announced that FDA approved the IND application of its novel experimental drug for the topical treatmen
Technoderma Medicines, Inc.is a clinical stage biopharmaceutical company.
The company's current core research and development programs include innovative drugs for the treatment of androgenic alopecia, eczema/atopic dermatitis, psoriasis and lupus. TDM-105795, the world's leading small-molecule drug candidate for the treatment of androgenic alopecia, has now completed 2a clinical trials. TDM-180935, a novel JAK1/TYK2 inhibitor for eczema/atopic dermatitis, also completed a Phase 1 clinical trial in December 2023 with favorable safety results.